Mono is a fastest way to the market. By the way this company is operated you cannot ignore this opportunity. As for SL, it might be true only for one or two mutated clones of certain cell line. BTW, no mechanism is offered. If they are serious about it, they should start a new Ven r/r cohort in their combo arm.
News 
Market Data 
Discover 
